Hims & Hers to 'treat multiple specialties,' not just weight loss
Despite a top-line fourth quarter beat and better-than-expected first quarter outlook, shares of Hims & Hers Health dropped, sparking concerns among investors. Hims & Hers CFO Yemi Okupe joins Josh Lipton and Julie Hyman on Asking for a Trend to discuss the company's growth and outlook. "We're seeing our model, which centers on providing access to personalized products and delighting subscribers through exceptional service, really resonating incredibly well with consumers — this is translating into very robust business performance," Okupe shares. The company reported $1.5 billion in revenue for 2024, with $1.2 billion from non-GLP-1 related sources. "Our aim at Hims and Hers is to build a robust platform that's able to treat multiple specialties; our aim is not to necessarily just be a weight-loss company," Okupe explains. Regarding regulatory changes, Okupe explains the company's commitment to compliance. "We do fully intend to abide by all regulatory requirements and when necessary to do so, will remove all commercially available dosages of semaglutide from the platform," he says, while still expressing confidence in the company's weight loss offerings. To watch more expert insights and analysis on the latest market action, check out more Asking for a Trend here. This post was written by Josh Lynch
